Literature DB >> 24159167

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.

Clémence Roux1, Franck-Emmanuel Nicolini, Delphine Rea, Mathilde Niault, Luigina Mollica, Françoise Berger, Catherine Chassagne-Clément, Isabelle Tigaud, Michel Tulliez, Stéphane Giraudier, Ali Turhan, Philippe Rousselot, Laurence Legros.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24159167     DOI： 10.1182/blood-2013-07-513879

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

1.  The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.

Authors:  Lucy C Fox; Katherine D Cummins; Ben Costello; David Yeung; Rebecca Cleary; Cecily Forsyth; Maciek Tatarczuch; Kate Burbury; Olga Motorna; Jake Shortt; Shaun Fleming; Andrew McQuillan; Anthony Schwarer; Rosemary Harrup; Amy Holmes; Sumita Ratnasingam; Kah-Lok Chan; Wei-Hsun Hsu; Asma Ashraf; Faye Putt; Andrew Grigg
Journal:  Blood Adv       Date:  2017-05-15

2.  EBV-Positive B-Cell Proliferations of Varied Malignant Potential: 2015 SH/EAHP Workshop Report-Part 1.

Authors:  Yasodha Natkunam; John R Goodlad; Amy Chadburn; Daphne de Jong; Dita Gratzinger; John K C Chan; Jonathan Said; Elaine S Jaffe
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

Review 3.  Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.

Authors:  Dilek Keskin; Sevil Sadri; Ahmet Emre Eskazan
Journal:  Drug Des Devel Ther       Date:  2016-10-13       Impact factor: 4.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.